Pralsetinib

CHEMBL4582651 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

533.6 g/mol

LogP

3.1

Phase

4

Pralsetinib is a highly selective RET kinase inhibitor that potently blocks oncogenic RET fusions and point mutations (including gatekeeper and solvent front mutations) driving tumor cell proliferation and survival in RET-altered cancers. It is approved for the treatment of RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer, and is under investigation in other RET-altered malignancies.

Berat Molekul

533,6000 g/mol

LogP

3,10

TPSA

136,00 Å²

Lipinski RO5

Lulus

Area Terapeutik

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Breast Cancer Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1

InChI

InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19-,27+/m0/s1

Molecular Formula

C27H32FN9O2

HBD / HBA

3 / 9

Ikatan yang Dapat Dirotasi

8

Atom Berat

39

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Pralsetinib is a highly selective RET kinase inhibitor that potently blocks oncogenic RET fusions and point mutations (including gatekeeper and solvent front mutations) driving tumor cell proliferation and survival in RET-altered cancers. It is approved for the treatment of RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer, and is under investigation in other RET-altered malignancies.

Yes, Pralsetinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4582651. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 129073603. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Mencari informasi yang ramah bagi pasien?

Pralsetinib di PillFYI

Struktur

Data Cepat

Rumus: C27H32FN9O2
Sinonim: 1

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.